
==== Front
JCO Precis Oncol
JCO Precis Oncol
po
PO
JCO Precision Oncology
2473-4284
Wolters Kluwer Health

38905571
PO.24.00174
10.1200/PO.24.00174
00149
Case Reports
MEK Inhibition in a Pilocytic Astrocytoma With a Rare KRAS Q61R Mutation in a Young Adult Patient: A Case Report
https://orcid.org/0000-0001-6671-3597
Roberto Katrina MD, FPNA 1
Keith Julia MD, FRCPC 2
Levine Adrian MD, FRCPC 3
Pirouzmand Farhad MD, MSc, FRCSC 4
Soliman Hany MD, FRCPC 5
Lim-Fat Mary Jane MD, MSc, FRCPC 1
1 Division of Neurology, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada
2 Department of Laboratory Medicine and Pathobiology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada
3 Department of Pediatric Laboratory Medicine, The Hospital for Sick Children, Toronto, ON, Canada
4 Division of Neurosurgery, Department of Surgery, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada
5 Department of Radiation Oncology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada
Mary Jane Lim-Fat, MD, MSc, FRCPC; Twitter: @mjlimfat; e-mail: maryjane.limfat@sunnybrook.ca.
2024
21 6 2024
21 6 2024
8 e240017415 3 2024
23 4 2024
10 5 2024
© 2024 by American Society of Clinical Oncology
2024
American Society of Clinical Oncology
https://creativecommons.org/licenses/by/4.0/ Licensed under the Creative Commons Attribution 4.0 License: http://creativecommons.org/licenses/by/4.0/

This case illustrates the utility and impact of molecular testing and molecular tumor board discussion in the management of AYA patients with brain tumors.

OPEN-ACCESSTRUE
==== Body
pmcIntroduction

Pilocytic astrocytoma (PA) is a circumscribed astrocytic neoplasm classified as a WHO grade 1 tumor that develops predominantly in children.1 It accounts for 15.9% of all CNS tumors among children and adolescents age 0-19 years with a median age of diagnosis at 11 years. The average annual age-adjusted incidence rate of PA is 1.10 in children (0-14 years), 0.28 in the adolescent and young adult (AYA) group (15-39 years), and 0.08 in older adults (40+ years).2 Mitogen-activated protein kinase (MAPK) pathway alterations, such as BRAF fusions, are central to its oncogenesis and targeted therapy with BRAF and MEK inhibitors has been increasingly used after demonstration of their safety and efficacy in clinical trials.3-5 In this report, we describe a case of a young adult female patient with a PA identified to have an oncogenic KRAS mutation treated with up-front MEK inhibition.

Case Presentation

A 28-year-old female patient with no significant medical or family history presented to the emergency department with a 3-month history of progressive nonremitting headaches, right-sided visual field defect, and lethargy. Magnetic resonance imaging (MRI) of the brain revealed a large multiloculated multicystic enhancing lesion in the suprasellar region associated with third ventricular obstruction and hydrocephalus (Fig 1). She was urgently taken to the operating room for a subtotal resection of the tumor. She tolerated the procedure well and was discharged with improved neurological status. Two weeks postoperatively, however, she was readmitted because of a first-ever generalized tonic-clonic seizure. Repeat neuroimaging indicated progressive obstructive hydrocephalus from the tumor which showed further increase in size from baseline. She thereafter underwent right frontal ventriculostomy and septostomy with external ventricular drainage insertion that was eventually converted into a right frontal ventriculoperitoneal shunt.

FIG 1. Magnetic resonance imaging of the brain: (A) Axial postcontrast at the level of the midbrain, (B) at the level of the hypothalamus, (C) at the level of the third ventricle, and (D) sagittal postcontrast. From left to right, the images show the treatment response as depicted in the significant reduction in size of the irregularly enhancing and multilobulated cystic suprasellar mass after 6 months of trametinib.

Pathology from her first surgery was consistent with PA, WHO grade 1. The microscopic sections showed the classic biphasic morphology of PA with areas of densely fibrillary background and elongated glial tumor nuclei alternating with areas of lesser cellularity with many tumor cells being round with examples of a pennies-on-a-plate pattern (Fig 2). On immunohistochemical staining, the fibrillary cytoplasmic processes immunolabeled with GFAP, the tumor cells were immunonegative for mIDH1 (R132H) and BRAF V600E, ATRX expression was retained, p53 labeling was variable, and the Ki67 proliferative index was approximately 10%. Molecular testing via Illumina TruSight RNA Pan-Cancer next-generation sequencing (NGS) did not reveal any BRAF fusions, but did show an oncogenic KRAS p.Q61R single-nucleotide variant.

FIG 2. Hematoxylin and eosin stained histology images showing (A) a biphasic morphology with compact fibrillary areas alternating with looser regions. (B) Many of the tumor cells in the looser areas have round, monomorphous nuclei, perinuclear clearing, and there are examples of a pennies-on-a-plate morphology (black arrow).

Her case was discussed at an institutional multidisciplinary tumor board and a national AYA molecular tumor board (MTB; Canadian AYA Neuro-Oncology Network). The consensus was that a trial of MEK inhibition using trametinib was reasonable given the otherwise large treatment field for radiation therapy. Through a compassionate access drug program, she was started on trametinib at an initial dose of 1 mg once per day, which was then increased to 1.5 mg once daily. She developed facial and truncal acneiform rash as a dermatological adverse effect of the drug. This was addressed with oral clindamycin and HydroVal 0.2% cream and is now well under control. Because of grade 3 aceniform rash, further escalation to the standard adult dose of 2 mg once daily was deferred after shared decision making to ensure better tolerability. Within 2 weeks of treatment, she had symptomatic relief of her headaches and improvement in her vision. Serial imaging was done, and her MRI after 6 months of therapy demonstrated an objective radiographic response (Fig 1).

Patient Publication Consent

The authors declare that informed consent to publish information and images was obtained from the patient.

Discussion

To the best of our knowledge, this is the first reported case of an oncogenic KRAS p.Q61R mutation in a noncerebellar PA with an objective response to trametinib. Advances in molecular diagnostics have increased our understanding of PA and have informed the treatment approach for this tumor type. MAPK pathway alterations are implicated in the majority of PA with the most common finding being KIAA1549::BRAF fusion (BK fusion).3 Other genetic alterations include other BRAF mutations or fusions, NF1 mutations, FGFR1 mutations or fusions, and NTRK fusions.6 Rarely, KRAS mutations, RAF1 fusions, ROS1 fusions, and other alterations of MET and RET are identified.1 There is an association between certain genetic alterations and the location of PA; for example, BRAF fusions are more frequent in the posterior fossa than in supratentorial lesions.3 This has been demonstrated in pediatric low-grade gliomas (pLGG), and BK fusion was shown to be an independent favorable prognostic factor.7 There is also a correlation between age and BRAF fusions as they seem to be less frequent in adults.8

The Kirsten rat sarcoma viral oncogene homolog (KRAS) protein is an essential intracellular signal transducer involved in several cellular pathways. Oncogenic KRAS therefore disrupts normal biological processes.9 In particular, it leads to increased proliferation rates of cells harboring the mutation through the constitutive activation of the MAPK pathway.10 KRAS mutations have been detected in numerous tumors and are frequent in pancreatic, colorectal, and lung carcinomas, but are very rare in PA.9 Only two cases out of a population-based cohort of 1,000 pLGG had a KRAS mutation, suggesting that it is an uncommon alteration.3 The KRAS p.Q61R mutation, located in the catalytic G-domain of the protein, is known to be oncogenic and is found in pancreatic, colorectal, thyroid, and lung cancers.11 Table 1 summarizes a few reported cases of PA with KRAS mutations.12-16

TABLE 1. Review of Reported KRAS Mutations in Pilocytic Astrocytoma

Citation	Age, Years	Sex	Tumor Location	KRAS Mutation	Other Alterations	
Cin et al12	11	—	Cerebellum	KRAS E63K	None	
1	—	Third ventricle	KRAS G12A	None	
Jones et al13	40	Female	Fourth ventricle	KRAS R73M, KRAS E63K	None	
22	Female	Cerebellum	KRAS L19F, KRAS Q22K	None	
Theeler et al14	46	Female	Thoracic	KRAS G12S	KIAA1549::BRAF fusion	
Reinhardt et al15	—	Female	Spinal	KRAS Q61H	None	
—	Female	Posterior fossa	KRAS V14A	None	
Chau et al16	24	—	Tectum	KRAS E63K	None	

PA has favorable clinical outcomes with 10-year-survival rates of up to 95%.1 The mainstay of treatment is gross total resection, which is not always feasible. For those with residual tumor, treatment recommendations in the 2023 National Comprehensive Cancer Network Guidelines for CNS Cancers include observation, consideration of radiotherapy for those who develop significant tumor growth and neurologic symptoms, or use of BRAF and MEK inhibitors in the presence of a BRAF V600E mutation.17 Prospective studies evaluating radiotherapy and chemotherapy in the adjuvant and recurrent setting among adult patients are lacking, and the effectiveness of pediatric chemotherapy regimens in adults is unknown.18 Moreover, there is risk of gonadal toxicity and higher risk of vincristine neurotoxicity in AYA and older adults when using the standard pediatric chemotherapy regimen of vincristine and carboplatin. As such, multidisciplinary tumor board discussion is crucial to guide treatment.

Two KRAS inhibitors, sotorasib and adagrasib, have been approved recently for use in KRAS G12C-mutant lung cancer.19,20 The role of KRAS inhibitors in targeted glioma therapy is unclear. Unfortunately, there is currently no effective treatment for primary brain tumors that targets KRAS and has demonstrated good intracranial activity. KRAS mutations in tumors may respond to MEK inhibitors such as trametinib, cometinib, or binimetinib. As MEK is a downstream effector of the MAPK pathway, MEK inhibitors have potential efficacy against tumors with RAS mutations and class I or II BRAF mutations. Monotherapy with a MEK inhibitor showed promising outcomes in pLGG with KIAA1549::BRAF fusion or NF1 loss of function.5 Meanwhile, dual therapy with dabrafenib and trametinib was found to be more effective and safe than standard chemotherapy with carboplatin plus vincristine as first-line therapy in pediatric patients with BRAF V600 mutant low-grade gliomas.4

Here, we describe the case of an AYA patient diagnosed with a KRAS-mutant PA in an unfavorable location treated with up-front targeted therapy using downstream signaling pathway blockade which had a positive outcome. MEK inhibition in a KRAS-mutant PA is a promising therapeutic strategy to postpone radiotherapy and thus avoid the risk of long-term neurocognitive impairment in a patient likely to have good long-term survival with appropriate treatment. The duration of MEK inhibition and durability of the treatment response in this patient is unknown, and longer follow-up is required.

The optimal approach to KRAS-mutant targeted therapy is unclear, and as demonstrated in this case, downstream inhibition may be considered. Additional data regarding the efficacy and outcomes of patients treated with molecularly directed therapies are needed especially in the AYA population which has unique clinical, molecular, and treatment considerations.21 This case suggests that the use of molecular testing such as NGS panels to identify targetable genetic alterations and therefore direct the selection of treatment is an important step in the management of AYA patients.22 Furthermore, this case illustrates the utility and impact of an MTB discussion on the interpretation and correct matching of targeted therapy to a genetic alteration. Finally, this case reiterates the challenges and treatment gap in the care of neuro-tumor AYA patients that remain to be addressed.

In conclusion, we present a case of an AYA patient with a PA harboring an unusual KRAS Q61R mutation in which up-front targeted therapy using a MEK inhibitor led to an impressive radiographic response and clinical improvement. In patients with excellent long-term survival, there is a need to identify potential adjuvant therapies with much less toxic side effects than the conventional radiotherapy and chemotherapy strategies available. Up-front targeted therapy is a promising treatment strategy to avoid or postpone these risks without compromising outcomes. MTB discussions are valuable in treatment selection, particularly in the AYA group, which is regarded as an orphan group with unique host and disease biology and age-related challenges.

AUTHOR CONTRIBUTIONS

Conception and design: Katrina Roberto, Hany Soliman, Mary Jane Lim-Fat

Provision of study materials or patients: Adrian Levine

Collection and assembly of data: Katrina Roberto, Julia Keith, Adrian Levine, Farhad Pirouzmand, Mary Jane Lim-Fat

Data analysis and interpretation: Katrina Roberto, Julia Keith, Mary Jane Lim-Fat

Manuscript writing: All authors

Final approval of manuscript: All authors

Accountable for all aspects of the work: All authors

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/po/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Julia Keith

Employment: Sunnybrook Health Sciences Center

Mary Jane Lim-Fat

Honoraria: Servier, Novocure

Consulting or Advisory Role: Canadian Agency for Drugs and Technologies in Health (CADTH), Cancer Care Ontario

No other potential conflicts of interest were reported.
==== Refs
REFERENCES

1. WHO: Central Nervous System Tumours WHO Classification of Tumours, Volume 6 (ed 5, WHO Classification of Tumours Editorial Board, ed). International Agency for Research on Cancer, 2021
2. Ostrom QT , Price M , Neff C , et al : CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2016—2020. Neuro Oncol 25 :iv1-iv99, 2023 (suppl 4 )37793125
3. Ryall S , Zapotocky M , Fukuoka K , et al : Integrated molecular and clinical analysis of 1,000 pediatric low-grade gliomas. Cancer Cell 37 :569-583.e5, 2020 32289278
4. Bouffet E , Hansford JR , Garrè ML , et al : Dabrafenib plus trametinib in pediatric glioma with BRAF V600 mutations. N Engl J Med 389 :1108-1120, 2023 37733309
5. Schreck KC , Grossman SA , Pratilas CA : BRAF mutations and the utility of RAF and MEK inhibitors in primary brain tumors. Cancers (Basel) 11 :1262, 2019 31466300
6. Milde T , Rodriguez FJ , Barnholtz-Sloan JS , et al .: Reimagining pilocytic astrocytomas in the context of pediatric low-grade gliomas. Neuro Oncol 23 :1634-1646, 2021 34131743
7. Hawkins C , Walker E , Mohamed N , et al : BRAF-KIAA1549 fusion predicts better clinical outcome in pediatric low-grade astrocytoma. Clin Cancer Res 17 :4790-4798, 2011 21610142
8. Hasselblatt M , Riesmeier B , Lechtape B , et al : BRAF-KIAA1549 fusion transcripts are less frequent in pilocytic astrocytomas diagnosed in adults. Neuropathol Appl Neurobiol 37 :803-806, 2011 21696415
9. Hajdúch M , Jančík S , Drábek J , et al : Clinical relevance of KRAS in human cancers. J Biomed Biotechnol 2010 :150960, 2010 20617134
10. Jones DTW , Gronych J , Lichter P , et al .: MAPK pathway activation in pilocytic astrocytoma. Cell Mol Life Sci 69 :1799-1811, 2012 22159586
11. Sweeney SM , Cerami E , Baras A , et al : AACR project genie: Powering precision medicine through an international consortium. Cancer Discov 7 :818-831, 2017 28572459
12. Cin H , Meyer C , Herr R , et al : Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma. Acta Neuropathol 121 :763-774, 2011 21424530
13. Jones DTW , Hutter B , Jäger N , et al : Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet 45 :927-932, 2013 23817572
14. Theeler BJ , Ellezam B , Sadighi ZS , et al : Adult pilocytic astrocytomas: Clinical features and molecular analysis. Neuro Oncol 16 :841-847, 2014 24470550
15. Reinhardt A , Stichel D , Schrimpf D , et al : Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations. Acta Neuropathol 136 :273-291, 2018 29564591
16. Chau LQ , Levy ML , Crawford JR .: Unusual KRAS missense mutation (p.E63K) in patient with juvenile pilocytic astrocytoma of the tectum. BMJ Case Rep 12 :e228128, 2019
17. National Comprehensive Cancer Network Inc: NCCN Clinical Practice Guidelines in Oncology (NNCN Guidelines®) for Central Nervous System Cancers (version 1.2023). NCCN Clinical PRactice Guide, 2023. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1425
18. Gregory TA , Chumbley LB , Henson JW , et al : Adult pilocytic astrocytoma in the molecular era: A comprehensive review. CNS Oncol 10 :CNS68, 2021 33448230
19. Nakajima EC , Drezner N , Li X , et al : FDA approval summary: Sotorasib for KRAS G12C-mutated metastatic NSCLC. Clin Cancer Res 28 :1482-1486, 2022 34903582
20. Dhillon S : Adagrasib: First approval. Drugs 83 :275-285, 2023 36763320
21. Yeo KK , Burgers DE , Brodigan K , et al : Adolescent and young adult neuro-oncology: A comprehensive review. Neurooncol Pract 8 :236-246, 2021 34055371
22. Lim-Fat MJ , Macdonald M , Lapointe S , et al : Molecular testing for adolescent and young adult central nervous system tumors: A Canadian guideline. Front Oncol 12 :960509, 2022 36249063
